Navigation Links
Ikaria Founding Scientist Named 2007 MacArthur Fellow
Date:9/26/2007

CLINTON, N.J., Sept. 26 /PRNewswire-USNewswire/ -- Mark Roth, Ph.D., an advisor and founding scientist of Ikaria, this week received a MacArthur Fellowship award, which includes a grant to further his research over the next five years.

Roth, a member of the Fred Hutchinson Cancer Research Center's Basic Sciences Division, received five years of "no-strings-attached" support from the John D. and Catherine T. MacArthur Foundation for his pioneering research in basic biology. Most notably, his research has pioneered reversible metabolic hibernation -- a finding that may have clinical benefits in humans.

"Mark is an extraordinarily talented scientist, as well as a great friend and colleague to the Ikaria team," said Ikaria Chairman and CEO David Shaw. "We are very pleased that the MacArthur Foundation recognized the importance of Mark's groundbreaking research through this prestigious award. We look forward to making the benefits of this research available to patients in the future."

In April 2005, Roth demonstrated the ability of the biological gas hydrogen sulfide to induce a state of reversible metabolic hibernation in mice, which may be a latent ability in all mammals. Temporary slowing of the metabolic rate, or inducing hibernation on demand, has the potential to lengthen the window of time that patients with trauma, stroke, cardiac arrest or surgery can be treated. In addition to increasing the time that transplant organs or tissues are viable outside the body, this expanded time window could help prevent injury and death from insufficient or inappropriate oxygen supply to organs and tissues.

Ikaria has submitted regulatory documents for hydrogen sulfide as an experimental drug. The company is expected to start a Phase I trial later this year.

The MacArthur Fellowship Program recognizes talented individuals who have shown exceptional originality and dedication in their creative pursuits. Its purpose is to invest in a person's "originality, insight, and potential," enabling recipients to exercise their own creative instincts for the benefit of human society. Since its start in 1981, the program has named 756 Fellows, including Roth, who was among the 24 recipients announced this week.

About Ikaria Holdings

Ikaria Holdings is a fully integrated biotherapeutics company focused on the development and commercialization of innovative in-hospital pharmaceutical products and drug/device combinations that improve the lives of patients. The company's INOmax(R) product (inhaled nitric oxide) is an FDA-approved drug for the treatment of pulmonary hypertension in newborns, and is extensively used in critical settings in the United States, Canada, Europe, Latin America and Asia. Ikaria has a staff of over 300 people and is headquartered in Clinton, N.J., with research facilities in Seattle and Madison, Wis., and manufacturing in Port Allen, La. For more information, please visit the company's Web site at http://www.ikaria.com.

To view a related press release from the Fred Hutchinson Cancer Research Center, visit http://www.fhcrc.org/about/ne/news/2007/09/25/roth.html

For more information on the MacArthur Fellowship Program, visit http://www.macfound.org/site/c.lkLXJ8MQKrH/b.855229/k.63D6/Macarthur_Founda tio n_Home.htm


'/>"/>
SOURCE Ikaria
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. UW computer scientists fighting computer virus "Cold War"
2. UW scientist, former WiCell director found stem cell company
3. Scientists find way to make human collagen in lab
4. Wisconsin scientists to be recognized for innovative biofuel technology
5. UW biophysical scientist honored as society fellow
6. UW scientist wins Pew grant to study little-known immune cells
7. UW-Madison scientists to mimic nature for newest cancer drugs
8. The Scientist magazine names Madison "hotspot" for biotechnology
9. UW scientists study strange material with communications potential
10. Scientists find nanotech method for examining cells
11. Scientist takes back patents and develops product others ignored
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/17/2017)... Yorba Linda, Ca (PRWEB) , ... July 17, ... ... highly heterogeneous and are characterized by a wide range of overlapping clinical features. ... pace of discovery in the field of NDD research and testing. , ...
(Date:7/16/2017)... (PRWEB) , ... July 16, 2017 , ... ... equipment and analytical instruments announced the launch of its new line of Rocking ... five rocking and waving shaker models (both analog and digital) for laboratory applications ...
(Date:7/14/2017)... ... July 13, 2017 , ... Dr. Joshua Mondlick has ... implants into his practice, Mondlick Perio, in the Phoenix area. Dr. Mondlick ... first and only FDA cleared laser treatment to re-grow bone and with significantly less ...
(Date:7/13/2017)... ... July 13, 2017 , ... ... in Specialty Pharmacy. URAC is the independent leader in promoting healthcare quality through ... comprehensive commitment to quality care, improved processes and better patient outcomes. , ...
Breaking Biology Technology:
(Date:4/5/2017)... Allen Institute for Cell Science today announces the launch ... dynamic digital window into the human cell. The website ... deep learning to create predictive models of cell organization, ... suite of powerful tools. The Allen Cell Explorer will ... resources created and shared by the Allen Institute for ...
(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... to expand at a CAGR of 25.76% during the ... is the primary factor for the growth of the ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem ... technology, application, and geography. The stem cell market of ...
(Date:4/3/2017)... April 3, 2017  Data captured by ... platform, detected a statistically significant association between ... to treatment and objective response of cancer ... to predict whether cancer patients will respond ... as well as to improve both pre-infusion potency ...
Breaking Biology News(10 mins):